X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.biospace.com/article/fda-rejects-viatris-mapi-s-long-acting-multiple-sclerosis-injection/
https://www.prnewswire.com/news-releases/viatris-and-mapi-pharma-announce-fda-acceptance-of-new-drug-application-filing-for-ga-depot-for-the-treatment-of-relapsing-forms-of-multiple-sclerosis-301894145.html
https://www.prnewswire.com/news-releases/viatris-and-mapi-pharma-to-highlight-latest-results-of-multiple-sclerosis-research-at-american-academy-of-neurology-75th-annual-meeting-301804983.html
https://www.globenewswire.com/news-release/2022/10/12/2533105/37187/en/Mapi-Pharma-to-Host-a-Key-Opinion-Leader-Webinar-on-Glatiramer-Acetate-Depot.html
https://www.globenewswire.com/news-release/2022/09/21/2520142/37187/en/Mapi-Pharma-Announces-Positive-Top-Line-Results-from-GA-Depot-Phase-III-Trial-for-Relapsing-forms-of-Multiple-Sclerosis-RMS.html
https://www.globenewswire.com/news-release/2022/03/31/2413924/37187/en/Mapi-Pharma-to-Present-Posters-on-GA-Depot-for-Treating-Relapsing-Forms-of-Multiple-Sclerosis-MS-and-Primary-Progressive-Forms-of-Multiple-Sclerosis-at-the-American-Academy-of-Neur.html
https://www.globenewswire.com/news-release/2022/03/30/2412788/37187/en/Mapi-Pharma-Receives-U-S-Patent-Covering-Methods-of-Suppressing-or-Alleviating-Primary-or-Secondary-Progressive-Multiple-Sclerosis-with-a-Sustained-Release-Glatiramer-Acetate-Depot.html
https://www.globenewswire.com/news-release/2021/10/21/2318365/37187/en/Mapi-Pharma-Signs-Agreement-with-Gaelan-Medical-Trade-LLC-to-Exclusively-Market-and-Distribute-Mapi-Products-in-UAE.html
https://mapi-pharma.com/mapi-pharma-provides-enrollment-update-in-phase-iii-ga-depot-clinical-trial/#:~:text=NESS%20ZIONA%2C%20Israel%20%E2%80%93%20Dec.,of%20Multiple%20Sclerosis%20(RMS).
https://www.globenewswire.com/news-release/2020/12/21/2148720/0/en/Mapi-Pharma-Provides-Enrollment-Update-in-Phase-III-GA-Depot-Clinical-Trial.html
Market Place
Share 
